arrow
J

Joseph Tintelnot

University Medical Center Hamburg-Eppendorf
H指数:12
被引数:965

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

既往与同期糖皮质激素和抗生素治疗对免疫治疗疗效的差异化影响——德国AIO研究组RAMONA、INTEGA、OPTIM、ELDORANDO、FORCE、TITAN-RCC和TITAN-TCC试验的合并分析

2026-05-190
OAAI
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial

围手术期帕博利珠单抗、曲妥珠单抗及FLOT方案在HER2阳性局限性食管胃腺癌中的疗效:一项Ⅱ期临床试验

2025-10-180
OAAI
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (vol 615, pg 168, 2023)

微生物群衍生的3-IAA影响胰腺癌化疗效果(卷 615,页 168,2023)

NATURE
IF48.5
2025-05-130
OA
Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial

局部晚期直肠癌中基于三氟尿苷/替匹拉西的放化疗: I/II期TARC试验

2025-03-010
OAAI
Steroid and antibiotic treatment are associated with diverse immunotherapy efficacy: A pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC trials of the German AIO study group

糖皮质激素和抗生素治疗与免疫治疗效果多样相关:德国AIO研究小组的RAMONA、INTEGA、OPTIM、ELDORANDO、FORCE、TITAN-RCC和TITAN-TCC试验的合并分析

2024-09-010
PRE
Efficacy and quality of life for FOLFOX/bevacizumab plus /- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial

FOLFOX/贝伐单抗联合/伊立替康治疗一线转移性结直肠癌的疗效和生活质量-AIO CHARTA试验的最终结果

2023-11-234
OA
CD4+T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis
2023-10-209
OA
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)

Pembrolizumab和曲妥珠单抗联合FLOT用于HER2-positive局部食管胃腺癌的围手术期治疗-AIO研究组 (AIO STO 0321) 的II期试验

2023-10-163
OAAI
Calcium channel ß3 subunit regulates ATP-dependent migration of dendritic cells

钙通道 β3亚基调节树突状细胞的ATP依赖性迁移

2023-09-227
OAAI
First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

不可切除或转移性HER2阳性食管胃腺癌的一线治疗: INTEGA 2期试验的液体生物标志物分析

2023-06-163
OAAI
IL-22BP controls the progression of liver metastasis in colorectal cancer
2023-05-311
OAAI
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

微生物来源的3-IAA影响胰腺癌的化疗效果

Nature
IF48.5
2023-02-220
OAAI
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
2023-01-1614
OA
Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
2022-12-2017
OAAI
Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)
2021-09-0110
OAAI
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
2021-07-2734
OAAI